NCT00724802

Oral Glyceryl Triacetate (GTA) in Newborns With Canavan

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 1 (estimated)
• Sponsor: Shaare Zedek Medical Center · Academic / Other
• Sex: All
• Age: 18 Months
• Healthy volunteers: Not accepted

Summary

Canavan disease is caused by Aspartoacylase deficiency. There is no treatment for the disease, but there is a food additive that includes acetate . We suggest an early treatment with acetate and a neurologic evaluation, including MRI, after 4 months of treatment. In any case the treatment will be stopped at the age of 22 months, when myelinization is ended.

Conditions

• Canavan Disease

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	GTA (Glyceryl triacetate)	0.5 gr/kg x2/day syrup two times a day with increasing dose each 3 days till max 5gr /kg each day for 6 months
DRUG	GTA glyceryl triacetate	0.5 gr/kg twice a day with increase of 0.5 gr/kg every 3 days up to 5 gr/kg

Timeline

• Start date: 2008-03-01
• Primary completion: 2008-08-01
• First posted: 2008-07-30
• Last updated: 2011-06-21

Locations

1 site across 1 country: Israel